不同术后辅助化疗方案对胃癌患者远期生存的影响

目的：比较奥沙利铂（L—OHP）联合5-FU／LV与羟基喜树碱（HCPT）联合5-FU／LV两种不同辅助化疗方案对可切除胃癌术后远期生存的影响。方法：85例I-Ⅳ期胃癌术后（R0切除）患者接受治疗，其中奥沙利铂组（L—OHP组）43例，羟基喜树碱组（HCPT组）42例，比较两组不良反应和生存率。结果：不良反应两组血小板减少、外周神经毒性及腹泻有显著性差异（P〈0．05），其它不良反应无统计学差异（P〉0．05）。L—OHP组及HCPT组1、3、5年总生存率（OS）分别为95．4％、67．4％、18．6％和92．9％、64．3％、21．4％，两组比较无显著性差异（P〉Q05），L—OHP组及HCPT组1、3、5年无病生存率（DFS）分别为83．7％、41．9％、9．3％和80．5％、45．2％、19．1％，随着时间延长，HCPT组5年DFS似有升高趋势，但均无统计学差异（P〉0．05）。结论：两种化疗方案均可作为胃癌患者术后辅助治疗的选择。

Impact of different adjuvant chemotherapy on long term survival of gastric cancer

Objective：To compare the long term survival of adjuvant chemotherapy of oxaliplatin （ L - OHP） or hydroxycamptothecine （HCPT） plus 5 - fluorouracil and leucovorin （ 5 - FU/LV） for stage I to stage IV resected gastric cancer. Methods： Total of 85 resected gastric cancer patients accepted the treatment. Among those,43 were treated by the approach of L - OHP and 5 - FU/LV ,42 were treated by the approach of HCPT and 5 - FU/LV. The adverse events and survival rate were compared. Results： The diversity of the two groups＇thrombocytopenia,perisen- sory nerve toxicity and diarrhea was obvious （P 〈 0.05 ）, but the diversity of other adverse events was not obvious （P 〉 0.05 ）. There was not significant difference between two groups in the overall survival （OS） of 1 year,3 years and 5 years （ P 〉 0.05 ）. The disease free survival （DFS） of 5 years had elevatory trend in group HCPT, but there was al- so not markedly difference（ P 〉 0.05 ）. Conclusion： Two combined chemotherapy approachs can all be selected as the adjuvant therapy for resected gastric cancer.